Acadia Pharmaceuticals Announces Executive Leadership Change
ACADIA Pharmaceuticals Inc. (ACAD)
Last acadia pharmaceuticals inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-irhome
Company Research
Source: Business Wire
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Elena Ridloff, Executive Vice President and Chief Financial Officer (CFO), will be leaving the company effective September 10, 2021 to join another biopharmaceutical company. Mark Schneyer, Senior Vice President, Business Development and Chief Business Officer, will serve as Acadia’s interim Chief Financial Officer. The company is conducting a formal search for a new CFO.“On behalf of all of us at Acadia, I want to thank Elena for her leadership and contributions which played an important role in supporting Acadia’s growth and long-term business strategy, and we wish her well in her future endeavors,” said Steve Davis, Chief Executive Officer.“I want to thank my colleagues at Acadia for their partnership in driving growth of the pimavanserin franchise and advancing important therapies in our pipeline,” said Ms. Ridloff. “I’m confident the experienced Acadia team will continue to deliver on
Show less
Read more
Impact Snapshot
Event Time:
ACAD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACAD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACAD alerts
High impacting ACADIA Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
ACAD
News
- Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada [Yahoo! Finance]Yahoo! Finance
- Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health CanadaBusiness Wire
- Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual MeetingBusiness Wire
ACAD
Earnings
- 2/27/24 - Miss
ACAD
Sec Filings
- 4/15/24 - Form 3
- 4/9/24 - Form 4
- 4/9/24 - Form 4
- ACAD's page on the SEC website